资源 » 参考数据库 » 客户发表文献

至今，GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次，处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果，再次证明GenScript 有能力帮助业内科学家Make research easy.

Inhibition of the aberrant A1CF-FAM224A-miR-590-3p-ZNF143 positive feedback loop attenuated malignant biological behaviors of glioma cells.

J. Exp. Clin. Cancer Res.. 2019-06;

SongYichen，ShaoLianqi，XueYixue，RuanXuelei，LiuXiaobai，YangChunqing，ZhengJian，ShenShuyuan，ChenJiajia，LiZhen，LiuYu

Products/Services Used	Details	Operation
Gene Synthesis	Full-length A1CF, FAM224A, ZNF143 and ASAP3 genes (A1CF (+), FAM224 (+), ZNF143 (+) and ASAP3 (+)) and their negative control (A1CF (+)-NC, FAM224 (+)-NC, ZNF143 (+)-NC and ASAP3 (+)-NC) were ligated into pIRES2-EGFP (GenScript, Piscataway, NJ, USA).	Get A Quote

摘要

Glioma is the most common and lethal type of malignant brain tumor. Accumulating evidence has highlighted that RNA binding protein APOBEC1 complementation factor (A1CF) is involved in various cellular processes by modulating RNA expression， and acts as an oncogene in breast cancer. However， the function of A1CF in glioma remained unclear.